Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma

Verified

Overview

This is a Phase I, FIH, open-label, dose escalation study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed or refractory multiple myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of one infusion of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

May 5, 2023: Cellectis has given up on its multiple myeloma CAR-T candidate UCARTCS1. With the phase 1 clinical trial two years behind schedule, and heavy investment needed to accelerate enrollment, the off-the-shelf cell therapy specialist is stopping the study and focusing its resources on three other candidates. Learn more

SparkCures ID 1038
Trial Phase Phase 1
Enrollment 18 Patients
Treatments
Tags
Trial Sponsors
  • Cellectis S.A.
NCT Identifier

NCT04142619

CLOSED

This trial is active but is no longer accepting patients.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patients with confirmed diagnosis of active multiple myeloma (as defined by International Myeloma Working Group [IMWG] criteria) who have relapsed after prior lines of therapy.
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1;
  • No previous treatment with investigational gene targeting CS1 or chimeric antigen receptor therapy targeting CS1
  • Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within the screening period.
  • Other criteria may apply

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers

Trial Links

Read the latest news and updates on this trial.

Cellectis' CAR-T Trial for Multiple Myeloma on Clinical Hold After Patient Death

July 07, 2020

Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its MELANI-01 trial.

Read more
View More Links
SparkCures Verified

SparkCures is working closely with Cellectis S.A. to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors